Matsui, Takanori

Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis

Ojima, A., Matsui, T., Nishino, Y., Nakamura, N., & Yamagishi, S. (2015) · Hormone and Metabolic Research

Chronic Kidney Disease and DiabetesAdvanced Glycation End Products research

Cited by 223

Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression

Ojima, A., Ishibashi, Y., Matsui, T., Maeda, S., Nishino, Y., Takeuchi, M., Fukami, K., & Yamagishi, S.-I. (2013) · The American Journal of Pathology

Advanced Glycation End Products researchChronic Kidney Disease and Diabetes

Cited by 156

Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects

Yamagishi, S.-I., Adachi, H., Nakamura, K., Matsui, T., Jinnouchi, Y., Takenaka, K., Takeuchi, M., Enomoto, M., Furuki, K., Hino, A., et al. (2006) · Metabolism

Advanced Glycation End Products researchChronic Kidney Disease and Diabetes

Cited by 148

Serum Levels of Advanced Glycation End Products (AGEs) are Independent Correlates of Insulin Resistance in Nondiabetic Subjects

Tahara, N., Yamagishi, S., Matsui, T., Takeuchi, M., Nitta, Y., Kodama, N., Mizoguchi, M., & Imaizumi, T. (2012) · Cardiovascular Therapeutics

Advanced Glycation End Products researchAdipokines, Inflammation, and Metabolic Diseases

Cited by 116

Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis

Nakashima, S., Matsui, T., Takeuchi, M., & Yamagishi, S.-I. (2014) · Hormone and Metabolic Research

Advanced Glycation End Products researchChronic Kidney Disease and Diabetes

Cited by 90

GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review

Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 60

Positive association of serum levels of advanced glycation end products and high mobility group box–1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients

Nakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Ueda, Y., Suzuki, T., Yamada, S., Takeuchi, M., Fukami, K., Ueda, S., et al. (2009) · Metabolism

Advanced Glycation End Products researchChronic Kidney Disease and Diabetes

Cited by 53

Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock

Nakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Suzuki, T., Ueda, Y., Yamada, S., Shoji, H., Takeuchi, M., Ueda, S., et al. (2009) · Pharmacological Research

Advanced Glycation End Products researchSepsis Diagnosis and Treatment

Cited by 46

Role of ligands of receptor for advanced glycation end products (RAGE) in peripheral artery disease

Yamagishi, S.-I., & Matsui, T. (2018) · Rejuvenation Research

Advanced Glycation End Products researchPeripheral Artery Disease Management

Cited by 31